ClinicalTrials.gg

Program

Fluorouracil

Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.

Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.

Furthest: phase 4, since Sep 14, 200634 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi160 open or runningphase 4since Sep 14, 2006Jan 6, 2001none ahead
Pfizer51 open or runningphase 3since Jan 28, 2000Jan 28, 2000none ahead
Jiangsu HengRui Medicine21 open or runningphase 3since Feb 20, 2023Mar 8, 2021none ahead
Otsuka20 open or runningphase 3since Jun 2, 2000Jun 2, 2000none ahead
prologue-research-international20 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Almirall10 open or runningphase 3since Nov 10, 2014Nov 10, 2014none ahead
cbsbioscience10 open or runningphase 2since Nov 10, 2016Nov 10, 2016none ahead
encube-ethicals-pvt-ltd10 open or runningphase 3since Sep 23, 2021Sep 23, 2021none ahead
healthcare-global-enterprise-ltd10 open or runningphase 2since Sep 29, 2016Sep 29, 2016none ahead
Sino Biopharmaceutical10 open or runningphase 3since Feb 25, 2019Feb 25, 2019none ahead
sol-gel-technologies-ltd10 open or runningphase 3since Oct 30, 2018Oct 30, 2018none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Nov 25, 2015Nov 25, 2015none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, parexel, Halozyme Therapeutics, biolinerx-ltd, baili-bio-chengdu-pharmaceutical-co-ltd, quintiles-inc, Takeda, almirall-hermal-gmbh and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Jan 28, 2000.

  1. Jan 28, 20083 phase 2 studiesSanofi · NCT00612495, NCT00611754, NCT00611507
  2. Oct 28, 2008Phase 2 study in Uterine NeoplasmsSanofi · NCT00782041 · 11 enrolled · Thailand
  3. Sep 22, 2009Phase 3 study in Head and Neck NeoplasmsSanofi · NCT00995293 · 240 enrolled · China
  4. Aug 14, 2013Phase 1 study in NeoplasmsSanofi · NCT01930552 · 20 enrolled · China
  5. Nov 10, 2014Almirall's first study: phase 3 study in Keratosis, ActinicNew to AlmirallAlmirall · NCT02289768 · 166 enrolled · Germany, United Kingdom
  6. Nov 25, 2015Teva Pharmaceutical Industries's first study: phase 3 study in Keratosis, ActinicNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02616601 · 422 enrolled · United States
  7. Sep 29, 2016healthcare-global-enterprise-ltd's first study: phase 2 study in Tongue NeoplasmsNew to healthcare-global-enterprise-ltdhealthcare-global-enterprise-ltd · NCT02985255 · 30 enrolled · India
  8. Nov 10, 2016cbsbioscience's first study: phase 2 study in Hepatocellular Carcinoma Non-ResectableNew to cbsbiosciencecbsbioscience · NCT02967887 · 96 enrolled · Korea, Republic of
  9. Oct 30, 2018sol-gel-technologies-ltd's first study: phase 3 study in Keratosis, ActinicNew to sol-gel-technologies-ltdsol-gel-technologies-ltd · NCT03727074 · 462 enrolled · United States
  10. Feb 25, 2019Sino Biopharmaceutical's first study: phase 3 study in Squamous Cell Carcinoma of Head and NeckNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03855384 · 334 enrolled · China
  11. Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
  12. Mar 8, 2021Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04796948 · 41 enrolled · China
  13. Sep 23, 2021encube-ethicals-pvt-ltd's first study: phase 3 study in Keratosis, ActinicNew to encube-ethicals-pvt-ltdencube-ethicals-pvt-ltd · NCT05078827 · 458 enrolled · United States
  14. Feb 20, 2023Phase 3 study in First-line Treatment of Advanced Pancreatic CancerJiangsu HengRui Medicine · NCT05751850 · 778 planned · China

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
TegafurruleOtsukaphase 325

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China3RecruitingJiangsu HengRui MedicineDec 30, 2024778
NCT05078827Keratosis, Actinic · United States3Completedencube-ethicals-pvt-ltdNov 1, 2022458
NCT04796948Advanced Pancreatic Cancer · China1CompletedJiangsu HengRui MedicineJun 28, 202441
NCT04607421Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerMar 1, 2025841
NCT03855384Squamous Cell Carcinoma of Head and Neck · China3UNKNOWNSino BiopharmaceuticalDec 31, 2020334
NCT03727074Keratosis, Actinic · United States3Completedsol-gel-technologies-ltdDec 19, 2019462
NCT02967887Hepatocellular Carcinoma Non-Resectable · Korea, Republic of2UNKNOWNcbsbioscienceOct 201896
NCT02985255Tongue Neoplasms · India2UNKNOWNhealthcare-global-enterprise-ltdJun 201730
NCT02616601Keratosis, Actinic · United States3CompletedTeva Pharmaceutical IndustriesSep 17, 2015422
NCT02289768Keratosis, Actinic · Germany, United Kingdom3CompletedAlmirallSep 2015166
NCT01930552Neoplasms · China1CompletedSanofiDec 201420
NCT00995293Head and Neck Neoplasms · China3CompletedSanofiJan 26, 2018240
NCT00782041Uterine Neoplasms · Thailand2TerminatedSanofiAug 200311
NCT00612495Endometrial Neoplasms · France2CompletedSanofi31
NCT00611754Head and Neck Neoplasms · France2CompletedSanofi15
NCT00611507Stomach Neoplasms · Colombia2CompletedSanofi21
NCT00559455Carcinoma, Hepatocellular · Korea, Republic of2CompletedSanofiJan 201038
NCT00555672Stomach Neoplasms · Spain1CompletedPfizerDec 200934
NCT00499850Adenocarcinoma · Australia1CompletedSanofiJun 200618
NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more3CompletedSanofiMar 2010371
NCT00401323Head and Neck Neoplasms · United States, Argentina, Australia and more3CompletedSanofiJun 2003568
NCT00382720Stomach Neoplasms · United States, Belgium, France and more2CompletedSanofiApr 2010275
NCT00377273Keratosis, Actinic · United States4CompletedSanofi250
NCT00343239Stomach Neoplasms · Turkey2CompletedSanofiMar 201259
NCT00261703Head and Neck Neoplasms · Portugal, Spain3CompletedSanofiJul 2010439
NCT00259402Esophageal Neoplasms · Spain2CompletedSanofiOct 200841
NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more3CompletedPfizerFeb 2008321
NCT00400179Stomach Neoplasms · United States, Canada3CompletedOtsukaMar 20081,053
NCT00062426Colorectal Neoplasms · United States3Completedprologue-research-international
NCT00026273Colorectal Neoplasms · Austria, Belgium, Egypt and more3CompletedPfizerSep 2004
NCT00016198Colorectal Neoplasms · United States2Completedprologue-research-internationalApr 2003
NCT00008281Colorectal Neoplasms · United States, Canada3UNKNOWNSanofi
NCT00005871Pancreatic Neoplasms · United States3UNKNOWNOtsuka
NCT00004252Colorectal Neoplasms · United States3CompletedPfizerSep 2007

How it is read

Names in the registry

  • “5-Fluorouracil”, 10 entries
  • “fluorouracil”, 9 entries
  • “Fluorouracil”, 8 entries
  • “5-fluorouracil”, 7 entries
  • “5-FU”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.